PREVIEW: The Impact of the Small Molecule “Pill Penalty” Two Years Into the IRA
- ccaplan7
- Jan 14
- 1 min read
Research firm Vital Transformation is preparing a new analysis about the impacts of the Inflation Reduction Act on biopharma investment, research and development in the two years since the law’s passage. Early returns show significant harms to innovation and patients’ treatment options, particularly because of the IRA’s small molecule “pill penalty.”